Form 4: EXELIXIS Director Sells Shares Under 10b5-1 Plan

EXELIXIS Director Sue Gail Eckhardt sold 3,856 shares of common stock for $43.79 per share under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Director Sue Gail Eckhardt of EXELIXIS, INC. sold 3,856 shares of common stock.
• The transaction occurred on February 13, 2026.
• The shares were sold at a weighted average price of $43.79 per share, with individual sales ranging from $42.89 to $43.89.
• The sale was executed under a Rule 10b5-1 trading plan adopted on November 11, 2025.
• Following the transaction, Ms. Eckhardt beneficially owns 17,524 shares, which includes restricted stock units (RSUs).

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. Insider sales under a 10b5-1 plan are typically pre-scheduled and do not necessarily reflect a change in the director's outlook on the company's future performance.

Positives

• The sale was conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a planned transaction rather than an immediate reaction to new information.

Negatives

• An insider sale, even under a 10b5-1 plan, reduces the director's direct ownership in the company.

Future Outlook

No specific future outlook or guidance is provided in this Form 4 filing.

Industry Context

StockSavvy.ai notes that insider sales under Rule 10b5-1 plans are common practice for corporate executives and directors to diversify their holdings and manage liquidity without being accused of trading on material non-public information. This particular transaction for EXELIXIS is a routine disclosure for a director in the biotechnology sector.

Comparison to Industry Standards

• This transaction is a standard insider disclosure for a director selling a relatively small portion of their holdings under a pre-arranged plan. It aligns with typical practices seen across publicly traded companies, including peers in the biotechnology industry such as Amgen (AMGN) or Gilead Sciences (GILD), where executives frequently use 10b5-1 plans for planned stock sales.

Related Party Transactions

• This filing reports a direct sale of shares by a director, which is a related party transaction by definition, but no other specific related party dealings are detailed.

Stakeholder Impact

• Shareholders: The sale by a director could be perceived negatively by some shareholders, though the 10b5-1 plan mitigates concerns about opportunistic selling. The impact is likely minimal given the size relative to the company's market cap.

Key Dates

Recommendation

This Form 4 filing details a routine insider sale under a pre-arranged 10b5-1 plan by a director. Such transactions are generally not considered indicative of a significant change in the company's fundamentals or future prospects. Therefore, it does not provide new information that would warrant a change in investment recommendation, suggesting a 'hold' position is appropriate based solely on this filing.

Keywords

EXELIXIS, EXEL, Form 4, Insider Sale, Director, Stock Transaction, 10b5-1 Plan, Equity, Biotech